Trials / Completed
CompletedNCT06979505
GV101 in Healthy Obese Participants
Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Graviton Bioscience Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GV101 | GV101 suspension |
| DRUG | GV101 placebo | GV101 placebo suspension |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2026-01-28
- Completion
- 2026-01-28
- First posted
- 2025-05-20
- Last updated
- 2026-02-04
Locations
20 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06979505. Inclusion in this directory is not an endorsement.